Nejim Besma, Hicks Caitlin W, Arhuidese Isibor, Locham Satinderjit, Dakour-Aridi Hanaa, Malas Mahmoud
Division of Vascular Surgery, Penn State Hershey Medical Center, Hershey, PA.
Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Johns Hopkins Medical Institutions, Baltimore, MD.
Ann Vasc Surg. 2020 Feb;63:209-217. doi: 10.1016/j.avsg.2019.04.026. Epub 2019 Jul 23.
Patients with end-stage renal disease (ESRD) whether on dialysis therapy (DT) or who received a kidney transplant (KT) have previously shown unfavorable surgical outcomes. Little is known about the comparative efficacy and durability of lower extremity bypass (LEB) in those patients. The Vascular Quality Initiative database was explored to identify DT or KT recipients (2003-2016) who had LEB. We included 1,714 bypass procedures; DT: 1,512 (88.2%). Primary patency (PP) at 2 year was comparable between KT and DT groups (PP [95% confidence interval {CI}]: 77.0% [69.7%-82.8%] vs. 80.5% [77.8%-82.9%]; P = 0.212), and the risk-adjusted hazard was similar (adjusted hazard ratio [aHR] [95% CI]: 0.89 [0.61-1.30]; P = 0.540). Amputation-free survival (AFS) at 2 year was more favorable in KT group (AFS [95% CI]: 73.1% [66.3%-78.8%] vs. 48.0% [45.4%-50.6%]; P < 0.001), (aHR [95% CI]: 2.29 [1.62-3.23]; P < 0.001). Patients on DT exhibited a higher risk of mortality than KT recipients (aHR [95% CI]: 2.94 [2.07-4.17]; P < 0.001). This study demonstrated superior limb outcomes in KT recipients than patients on DT after LEB. Despite the comparable PP, the risk of amputation or death was doubled in patients on DT compared with KT recipients. Because both groups were similar in several baseline characteristics, the difference in outcome is likely driven by the positive effect of KT on the physiological milieu of these patients.
终末期肾病(ESRD)患者,无论接受透析治疗(DT)还是接受肾移植(KT),既往均显示手术结局不佳。对于这些患者下肢旁路移植术(LEB)的比较疗效和耐久性知之甚少。我们通过血管质量倡议数据库,识别出接受过LEB的DT或KT受者(2003 - 2016年)。我们纳入了1714例旁路手术;其中DT患者1512例(88.2%)。KT组和DT组2年时的原发性通畅率(PP)相当(PP[95%置信区间{CI}]:77.0%[69.7% - 82.8%] vs. 80.5%[77.8% - 82.9%];P = 0.212),风险调整后的风险相似(调整后风险比[aHR][95% CI]:0.89[0.61 - 1.30];P = 0.540)。KT组2年时的无截肢生存率(AFS)更优(AFS[95% CI]:73.1%[66.3% - 78.8%] vs. 48.0%[45.4% - 50.6%];P < 0.001),(aHR[95% CI]:2.29[1.62 - 3.23];P < 0.001)。接受DT治疗的患者比KT受者有更高的死亡风险(aHR[95% CI]:2.94[2.07 - 4.17];P < 0.001)。本研究表明,LEB术后KT受者的肢体结局优于接受DT治疗的患者。尽管PP相当,但与KT受者相比,接受DT治疗的患者截肢或死亡风险增加了一倍。由于两组在几个基线特征方面相似,结局差异可能是由KT对这些患者生理环境的积极影响所致。